Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2020
ICER releases evidence report on treatments for cystic fibrosis
27 April 2020 - Evidence on Trikafta provides high confidence of a substantial net health benefit for patients; additional benefits accrue ...
Posted by Michael Wonder on 16 Apr 2020
ICER Appoints Yvette Venable as Vice President of Patient Engagement
16 April 2020 - The Institute for Clinical and Economic Review has announced the appointment of Yvette Venable as the organisation’s ...
Posted by Michael Wonder on 19 Mar 2020
Getting value right: the case for indirect benefits
19 March 2020 - According to the most recent estimates from the Centers for Medicare and Medicaid Services Office of the ...
Posted by Michael Wonder on 19 Mar 2020
ICER releases draft evidence report on obeticholic acid for non-alcoholic steatohepatitis
19 March 2020 - Public comment period on preliminary draft now open until 24 June 2020; requests to make oral comment ...
Posted by Michael Wonder on 18 Mar 2020
ICER indefinitely postpones public meetings for sickle cell disease and cystic fibrosis; expands other assessment timelines up to three months
18 March 2020 - Updated schedules are intended to enable participating clinical experts and patient advocates to focus on caring for ...
Posted by Michael Wonder on 15 Mar 2020
ICER posts draft scoping documents on bladder cancer and digital apps for opioid use disorder
13 March 2020 - Documents open to public comment until 2 April 2020. ...
Posted by Michael Wonder on 24 Feb 2020
ICER and Aetion partner to develop real-world evidence for value assessment of treatments
24 February 2020 - ICER adopts Aetion’s Real-World Evidence Platform — advancing standards for the use of transparent, replicable real-world ...
Posted by Michael Wonder on 20 Feb 2020
ICER to assess treatments for bladder cancer
20 February 2020 - Report will be subject of a Midwest CEPAC meeting in September 2020; open Input now being ...
Posted by Michael Wonder on 20 Feb 2020
ICER releases draft evidence report on therapies for cystic fibrosis
20 February 2020 - Public comment period now open until 18 March 2020; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 12 Feb 2020
ICER methods could be illegal in US, claims US think tank
11 February 2020 - The method used by the US Institute for Clinical and Economic Review (ICER) to gauge whether ...
Posted by Michael Wonder on 02 Feb 2020
ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework
31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...
Posted by Michael Wonder on 25 Jan 2020
ICER posts draft scoping document for the assessment of treatments for haemophilia A
24 January 2020 - Document open to public comment until 13 February 2020. ...
Posted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
Posted by Michael Wonder on 10 Jan 2020
ICER releases evidence report on acute treatments for migraine
10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...
Posted by Michael Wonder on 09 Jan 2020
ICER issues final report and policy recommendations on JAK inhibitors for rheumatoid arthritis
9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on ...